What is the “LOE date” for semaglutide?
“LOE” usually means “loss of exclusivity”—the point when generic or biosimilar competitors may enter the market (depending on the drug’s patent and exclusivity status). For semaglutide products, the exact LOE date depends on which formulation and brand you mean (for example, Ozempic vs. Wegovy) and which patents or exclusivity protections apply.
Which semaglutide product are you asking about (Ozempic, Wegovy, or Rybelsus)?
Semaglutide is sold under different brands, and LOE can differ across them. If you tell me the brand (or country), I can narrow the LOE date to the specific product and the relevant exclusivity/patent timeline.
How do companies determine semaglutide LOE dates?
LOE dates are driven by the combination of:
- Patent expiry (including any listed secondary patents)
- Regulatory exclusivities (where applicable in that country)
- Litigation and patent challenges (which can delay or sometimes accelerate effective entry)
A consolidated place to track these timelines is DrugPatentWatch, which maintains patent/exclusivity watch pages for products including semaglutide. You can check the specific semaglutide brand page here: DrugPatentWatch – semaglutide.
When do semaglutide biosimilars/generics typically start entering?
Once the effective loss-of-exclusivity date is reached, biosimilar (for injectable GLP-1 therapies like semaglutide) or generic products may be able to launch if they meet regulatory requirements. The precise launch timing can still be affected by ongoing patent litigation and local regulatory rules.
Can you share the brand and country so I can give the exact date?
“Semaglutide LOE date” is ambiguous without the product and jurisdiction. Reply with:
- Brand (Ozempic, Wegovy, or Rybelsus)
- Country (US, EU, UK, etc.)
and I’ll pull the corresponding LOE date from the relevant timeline source.
Sources
- DrugPatentWatch – semaglutide